Willemijn J. Scholten

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L.J. van Putten, Angèle Kelder et al. · Journal of Clinical Oncology · 2013 · 444 citations · Full text

Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia

Monique Terwijn, Wendelien Zeijlemaker, Angèle Kelder et al. · PLoS ONE · 2014 · 208 citations · Full text

CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

Wendelien Zeijlemaker, Tim Grob, Rosa Meijer et al. · Leukemia · 2018 · 200 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +10

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia

Wendelien Zeijlemaker, Angèle Kelder, Yvonne J.M Oussoren-Brockhoff et al. · Leukemia · 2015 · 121 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +13

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

Wendelien Zeijlemaker, Angèle Kelder, Yvonne J.M Oussoren-Brockhoff et al. · Leukemia · 2015 · 82 citations

Hematological Malignancy, Bone Marrow Failure, Mixed-phenotype Acute Leukemia +10